Event calendar

Event calendar

View recent presentations and learn more about upcoming events.
View of Banting 1 building - laboratory in Basel campus 10

First quarter results 2025

April 29, 2025 | Basel, Switzerland

Media release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)
Interim financial report (PDF 0.3 MB)

Watch the webcast
Download the podcast (MP3 32 MB)
Download the presentation (PDF 3.7 MB)
Download 2025 epidemiology data (PDF 2.0 MB)
Novartis Q1 2025 impact and sustainability update (PDF 0.9 MB)

Learn more
Upcoming events

 New York, USA

Miami, USA

Interlaken, Switzerland

London, UK

London, UK

Basel, Switzerland

Basel, Switzerland

London, UK

Event Calendar - 2025 Events

May 28, 2025
New York, USA

May 27, 2025
Frankfurt, Germany

May 15, 2025
Toronto, Canada

May 13-14, 2025
Las Vegas, USA

March 20, 2025
Zurich, Switzerland

March 12, 2025
Miami, USA

March 07, 2025
Basel, Switzerland

Visit the General Meetings section

March 04, 2025
Boston, USA

March 04, 2025
London, UK

January 31, 2025
Basel, Switzerland

Media release: English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)

Condensed financial report (PDF 0.5 MB)

Watch the webcast

Download the podcast (MP3 30 MB)

Download the presentation (PDF 4.7 MB)

Read the transcript 

Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)

January 14, 2025 
San Francisco, USA

Novartis CEO Vas Narasimhan presented at the J.P. Morgan Healthcare Conference.

Download the presentation (PDF 2.3 MB)

Download the podcast (MP3 18 MB)

Event Calendar - 2024 Events

December 09, 2024
Virtual event

Novartis 11th annual ESG investor event

Watch the webcast

Download the presentation (PDF 1.9 MB)

December 04, 2024
Miami, USA

November 21, 2024
London, UK

Read the media release

Watch the webcast

Download the webcast agenda (PDF 0.1 MB)

Download the speaker slides (PDF 0.8 MB)

Download the CEO presentation (PDF 1.2 MB)

Download the breakout slides (PDF 0.3 MB)

November 13, 2024
London, UK

November 12, 2024
Ranchos Palo Verdes, USA

November 12, 2024
Boston, USA

November 08, 2024
Zurich, Switzerland

October 29, 2024
Basel, Switzerland

Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.5 MB)
Interim financial report (PDF 0.6 MB)

Watch the webcast

Download the podcast (MP3 31 MB)

Download the presentation (PDF 6.8 MB)

Read the transcript

Novartis Q3 2024 impact and sustainability update (PDF 0.6 MB)

October 28, 2024
Virtual

Download the presentation (PDF 1.4 MB)

Watch the webcast

Download the podcast (MP3 30 MB)

September 26, 2024
Munich, Germany

September 25, 2024
Paris, France

September 18, 2024
London, UK

September 05, 2024
New York, USA

July 18, 2024
Basel, Switzerland

Media release:
English (PDF 0.5 MB) | Deutsch (PDF 0.5 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.5 MB

Watch the webcast

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q2 2024 impact and sustainability update (PDF 0.9 MB)

June 27, 2024
Lyon, France

June 20, 2024
London, UK

June 19, 2024
London, UK

June 11, 2024
Miami, USA

June 06, 2024
New York, USA

June 02, 2024
Chicago, USA

Download the presentation (PDF 1.0 MB)

Read the media release: Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

May 29, 2024
New York, USA

May 23, 2024
Frankfurt, Germany

May 21, 2024
New York, USA

May 20, 2024
Brooklyn, USA

May 15, 2024
Toronto, Canada

May 15, 2024
Las Vegas, USA

April 23, 2024
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.4 MB)

Interim financial report (PDF 0.4 MB)

Download the podcast (MP3 30 MB)

Download the presentation (PDF 6.0 MB)

Read the transcript

Novartis Q1 2024 impact and sustainability update (PDF 1.4 MB)

March 26, 2024
Virtual

March 26, 2024
Paris, France

March 21, 2024
Zurich, Switzerland

March 06, 2024
Boston, USA

March 05, 2024
Basel, Switzerland

Visit the General Meetings section

February 28, 2024
London, UK

January 31, 2024
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.6 MB)

Download the podcast (MP3 34 MB)

Download the presentation (PDF 5.5 MB)

Read the transcript

Novartis Q4 2023 impact and sustainability update (PDF 0.6 MB)

2023 epidemiology data (PDF 1.1 MB)

January 08, 2024
San Francisco, USA 

Download the presentation (PDF 1.3 MB)

Download the podcast (MP3 18 MB)

Read the featured news

Event Calendar - 2023 Events

November 28, 2023
London, UK

Read the media release

Download the podcast (MP3 102 MB)

Access our interactive presentation (PDF 17 MB)

November 15, 2023
London, UK

November 13, 2023

Novartis 10th annual ESG investor event

Download the presentation (PDF 9.9 MB)
 

November 08, 2023
Miami, USA

October 24, 2023
Basel, Switzerland

Media release:
English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB) | Français (PDF 0.5 MB)

Interim financial report (PDF 0.6 MB)

Download the podcast (MP3 33 MB)

Download the interactive presentation (PDF 3.5 MB)

Novartis Q3 2023 Impact and Sustainability Update (PDF 1.0 MB)

October 24, 2023
Basel, Switzerland

Download the podcast (MP3 24 MB)

Download the presentation (PDF 1.0 MB)

October 10, 2023

Download the presentation (PDF 0.4 MB)

September 15, 2023 
Basel, Switzerland

Visit the General Meetings section

Sep 13, 2023
London, UK

Sep 12, 2023
New York, USA

September 06, 2023
Boston, USA

July 18, 2023
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the interactive presentation (PDF 3.4 MB)

Download the podcast (MP3 34 MB)

Read the presentation transcript

Novartis Q2 2023 Impact and Sustainability Update (PDF 0.3 MB)

June 29, 2023
Bordeaux, France

June 22, 2023
London, UK

June 21, 2023
London, UK

June 12, 2023
Dana Point, USA

June 08, 2023
New York, USA

Download the podcast (MP3 160 MB)

June 12, 2023
London, UK

Download the podcast (MP3 111 MB)

Read the media release

Download the presentation (PDF 11 MB)

June 04, 2023
Chicago, USA

Read the media release

Download the presentation (PDF 1.2 MB)

May 09, 2023
Las Vegas, USA

April 26, 2023

Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities and the Coartem® brand from Sandoz to the Innovative Medicines Division, which were effective as of January 1, 2023. The 2022 updated segment financial reporting is provided in accordance with requirements of IFRS, and to aid comparability of 2023 quarterly and full year results for the segments and Corporate.

Download the presentation (PDF 0.4 MB)

April 25, 2023
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.3 MB)

Download the interactive presentation (PDF 3.4 MB)

Download the podcast (MP3 34 MB)

Read the presentation transcript

Novartis Q1 2023 Impact and Sustainability Update (PDF 1.9 MB)

March 14, 2023
Miami, USA

March 07, 2023
Basel, Switzerland

Visit the General Meetings section

March 07, 2023
Boston, USA

March 01, 2023
London, UK

February 21, 2023
Virtual

February 14, 2023
Virtual

February 08, 2023
Virtual

February 01, 2023
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Condensed financial report (PDF 0.5 MB)

Download the presentation (PDF 5.1 MB)

Download the podcast (MP3 45 MB)

Read the presentation transcript

Novartis ESG Update Q4 2022 (PDF 0.9 MB)

January 09, 2023
San Francisco, USA

Download the presentation (PDF 2.7 MB)

Download the podcast (MP3 18 MB)
 

 

Event Calendar - 2022 Events

December 13, 2022
Basel, Switzerland

Download the presentation (PDF 0.9 MB)

Download the podcast (MP3 24 MB)

Read the media release

December 07, 2022
London, UK

December 01, 2022
Paris, France

November 30, 2022
Basel, Switzerland

Download the presentation (PDF 1.6 MB)

 

November 16, 2022
London, UK

November 09-10, 2022
Palos Verdes, USA

November 09, 2022
London, UK

October 25, 2022
Basel, Switzerland

Media release:
English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB) | Français (PDF 0.3 MB)

Interim financial report (PDF 0.5 MB)

Download the presentation (PDF 3.7 MB)

Download the podcast (MP3 40 MB)

Read the presentation transcript

Novartis ESG Update - October 31, 2022 (PDF 0.5 MB)

September 28, 2022
London, UK

September 21-22, 2022
Basel, Switzerland

Download the agenda (PDF 0.2 MB)

Download the interactive presentation (PDF 4.7 MB)

Download the speakers slides (PDF 0.5 MB)

Read the media release
 

September 14, 2022
London, UK

September 12, 2022
New York, USA

August 25, 2022
Basel, Switzerland

Download the podcast (MP3 28 MB)

Download the presentation (PDF 1.1 MB)

Read the media release: English | Deutsch

July 19, 2022
Basel, Switzerland

Media release:
English (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.2 MB)

Interim financial report (PDF 0.5 MB)

Download the presentation (PDF 2.9 MB)

Download the podcast (MP3 42 MB)

Read the presentation transcript

Novartis ESG Update - July 20, 2022 (PDF 0.4 MB)

June 23, 2022
London, UK

June 15, 2022
London, UK

June 14, 2022
Palos Verdes, USA

June 10, 2022
New York, USA

June 09, 2022
New York, USA

June 02, 2022
New York, USA

Source URL: https://prod1.novartis.com/investors/event-calendar

List of links present in page
  1. https://prod1.novartis.com/investors/event-calendar
  2. https://prod1.novartis.com/sites/novartis_com/files/q1-2025-media-release-en.pdf
  3. https://prod1.novartis.com/sites/novartis_com/files/q1-2025-media-release-de.pdf
  4. https://prod1.novartis.com/sites/novartis_com/files/2025-04-interim-financial-report-en.pdf
  5. https://edge.media-server.com/mmc/p/8oygwmc4
  6. https://prod1.novartis.com/sites/novartis_com/files/2025-05/q1-2025-investor-presentation.mp3
  7. https://prod1.novartis.com/sites/novartis_com/files/q1-2025-investor-presentation.pdf
  8. https://prod1.novartis.com/sites/novartis_com/files/novartis-target-patient-populations-2025.pdf
  9. https://prod1.novartis.com/sites/novartis_com/files/novartis-q1-2025-impact-and-sustainability-update.pdf
  10. https://prod1.novartis.com/investors/financial-data/quarterly-results
  11. #tabrecent-events-415496
  12. #tab2024-archive-264806
  13. #tab2023-archive-139176
  14. #tab2022-archive-43351
  15. https://prod1.novartis.com/node/666161
  16. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  17. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-en.pdf
  18. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-media-release-de.pdf
  19. https://prod1.novartis.com/sites/novartis_com/files/2025-01-interim-financial-report-en.pdf
  20. https://edge.media-server.com/mmc/p/7vboajm5/
  21. https://prod1.novartis.com/sites/novartis_com/files/2025-02/q4-2024-investor-presentation.mp3
  22. https://prod1.novartis.com/sites/novartis_com/files/q4-2024-investor-presentation.pdf
  23. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript
  24. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2024-impact-and-sustainability-update.pdf
  25. https://prod1.novartis.com/sites/novartis_com/files/novartis-investor-presentation-jpm-2025-growth-story.pdf
  26. https://prod1.novartis.com/sites/novartis_com/files/2025-01/novartis-investor-presentation-jpm-2025-growth-story.mp3
  27. https://prod1.novartis.com/node/666161/printable/print
  28. https://prod1.novartis.com/node/666161/printable/pdf
  29. https://prod1.novartis.com/node/662281
  30. https://novartis.webcasts.com/starthere.jsp?ei=1689776&tp_key=9312b9a422
  31. https://prod1.novartis.com/sites/novartis_com/files/2024-12-novartis-impact-sustainability.pdf
  32. https://prod1.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-core-therapeutic-areas-drive-long-term-growth
  33. https://edge.media-server.com/mmc/p/mfs4d9bz
  34. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-agenda.pdf
  35. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-speaker-slides.pdf
  36. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-ceo-presentation.pdf
  37. https://prod1.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-breakout-slides.pdf
  38. https://prod1.novartis.com/sites/novartis_com/files/q3-2024-media-release-en.pdf
  39. https://prod1.novartis.com/sites/novartis_com/files/q3-2024-media-release-de.pdf
  40. https://prod1.novartis.com/sites/novartis_com/files/2024-10-interim-financial-report-en.pdf
  41. https://edge.media-server.com/mmc/p/3hsrpsa4
  42. https://prod1.novartis.com/sites/novartis_com/files/2024-10/q3-2024-investor-presentation.mp3
  43. https://prod1.novartis.com/sites/novartis_com/files/q3-2024-investor-presentation.pdf
  44. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q3-transcript
  45. https://prod1.novartis.com/sites/novartis_com/files/novartis-q3-2024-impact-and-sustainability-update.pdf
  46. https://prod1.novartis.com/sites/novartis_com/files/2024-10-novartis-renal-portfolio-presentation.pdf
  47. https://edge.media-server.com/mmc/p/d4yyo26k
  48. https://prod1.novartis.com/sites/novartis_com/files/2024-10/2024-10-novartis-renal-portfolio-presentation.mp3
  49. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-en.pdf
  50. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-de.pdf
  51. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-media-release-fr.pdf
  52. https://prod1.novartis.com/sites/novartis_com/files/2024-07-interim-financial-report-en.pdf
  53. https://edge.media-server.com/mmc/p/a2y6rkfr
  54. https://prod1.novartis.com/sites/novartis_com/files/2024-07/q2-2024-investor-presentation.mp3
  55. https://prod1.novartis.com/sites/novartis_com/files/q2-2024-investor-presentation.pdf
  56. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q2-transcript
  57. https://prod1.novartis.com/sites/novartis_com/files/novartis-q2-2024-impact-and-sustainability-update.pdf
  58. https://prod1.novartis.com/sites/novartis_com/files/2024-novartis-asco-investor-event-presentation.pdf
  59. https://prod1.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml
  60. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-en.pdf
  61. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-de.pdf
  62. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-media-release-fr.pdf
  63. https://prod1.novartis.com/sites/novartis_com/files/2024-04-interim-financial-report-en.pdf
  64. https://prod1.novartis.com/sites/novartis_com/files/2024-04/q1-2024-investor-presentation.mp3
  65. https://prod1.novartis.com/sites/novartis_com/files/q1-2024-investor-presentation.pdf
  66. https://prod1.novartis.com/investors/financial-data/quarterly-results/2024-q1-transcript
  67. https://prod1.novartis.com/sites/novartis_com/files/novartis-q1-2024-impact-and-sustainability-update.pdf
  68. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  69. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-en.pdf
  70. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-de.pdf
  71. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-media-release-fr.pdf
  72. https://prod1.novartis.com/sites/novartis_com/files/2024-01-interim-financial-report-en.pdf
  73. https://prod1.novartis.com/sites/novartis_com/files/2024-02/q4-2023-investor-presentation.mp3
  74. https://prod1.novartis.com/sites/novartis_com/files/q4-2023-investor-presentation.pdf
  75. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q4-and-full-year-results-transcript
  76. https://prod1.novartis.com/sites/novartis_com/files/novartis-q4-2023-impact-and-sustainability-update.pdf
  77. https://prod1.novartis.com/sites/novartis_com/files/novartis-target-patient-populations-2023.pdf
  78. https://prod1.novartis.com/sites/novartis_com/files/2024-jpm-novartis-strategy-growth-update.pdf
  79. https://prod1.novartis.com/sites/novartis_com/files/2024-01/2024-jpm-novartis-strategy-growth-update.mp3
  80. https://prod1.novartis.com/news/jp-morgan-healthcare-conference-2024
  81. https://prod1.novartis.com/node/662281/printable/print
  82. https://prod1.novartis.com/node/662281/printable/pdf
  83. https://prod1.novartis.com/node/546201
  84. https://prod1.novartis.com/news/media-releases/novartis-upgrades-mid-term-sales-growth-guidance-showcases-its-differentiated-innovative-medicines-strategy-and-robust-pipeline-rd-day
  85. https://prod1.novartis.com/sites/novartis_com/files/2023-12/novartis-investors-r-d-day-2023.mp3
  86. https://prod1.novartis.com/sites/novartiscom/files/novartis-investors-r-d-day-2023.pdf
  87. https://prod1.novartis.com/sites/novartiscom/files/2023-11-novartis-investor-impact-health-equity.pdf
  88. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-media-release-en.pdf
  89. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-media-release-de.pdf
  90. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-media-release-fr.pdf
  91. https://prod1.novartis.com/sites/novartis_com/files/2023-10-interim-financial-report-en.pdf
  92. https://prod1.novartis.com/sites/novartis_com/files/2023-10/q3-2023-investor-presentation.mp3
  93. https://prod1.novartis.com/sites/novartis_com/files/q3-2023-investor-presentation.pdf
  94. https://prod1.novartis.com/sites/novartis_com/files/novartis-q3-2023-impact-and-sustainability-update.pdf
  95. https://prod1.novartis.com/sites/novartis_com/files/2023-10/2023-novartis-esmo-call-presentation.mp3
  96. https://prod1.novartis.com/sites/novartis_com/files/2023-novartis-esmo-call-presentation.pdf
  97. https://prod1.novartis.com/sites/novartis_com/files/novartis-results-continuing-operations-october-2023.pdf
  98. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  99. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-media-release-en.pdf
  100. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-media-release-de.pdf
  101. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-media-release-fr.pdf
  102. https://prod1.novartis.com/sites/novartis_com/files/2023-07-interim-financial-report-en.pdf
  103. https://prod1.novartis.com/sites/novartis_com/files/q2-2023-investor-presentation.pdf
  104. https://prod1.novartis.com/sites/novartis_com/files/2023-07/q2-2023-investor-presentation.mp3
  105. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q2-transcript
  106. https://prod1.novartis.com/sites/novartis_com/files/novartis-q2-2023-impact-and-sustainability-update.pdf
  107. https://prod1.novartis.com/sites/novartis_com/files/2023-06/sandoz-capital-markets-day-new-york.mp3
  108. https://prod1.novartis.com/sites/novartis_com/files/2023-06/sandoz-capital-markets-day-london.mp3
  109. https://prod1.novartis.com/news/media-releases/sandoz-presents-compelling-investment-proposition-standalone-company-capital-markets-day
  110. https://prod1.novartis.com/sites/novartis_com/files/2023-sandoz-capital-markets-day-presentation.pdf
  111. https://prod1.novartis.com/news/media-releases/novartis-kisqali-significantly-reduced-risk-recurrence-25-across-broad-population-patients-early-breast-cancer-clinically-meaningful-benefit-was-consistent-across-subgroups
  112. https://prod1.novartis.com/sites/novartis_com/files/2023-06-novartis-asco-presentation.pdf
  113. https://prod1.novartis.com/sites/novartis_com/files/novartis-2022-financials-updated-segment-reporting-april-2023.pdf
  114. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-media-release-en.pdf
  115. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-media-release-de.pdf
  116. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-media-release-fr.pdf
  117. https://prod1.novartis.com/sites/novartis_com/files/2023-04-interim-financial-report-en.pdf
  118. https://prod1.novartis.com/sites/novartis_com/files/q1-2023-investor-presentation.pdf
  119. https://prod1.novartis.com/sites/novartis_com/files/2023-04/q1-2023-investor-presentation.mp3
  120. https://prod1.novartis.com/investors/financial-data/quarterly-results/2023-q1-transcript
  121. https://prod1.novartis.com/sites/novartis_com/files/novartis-q1-2023-impact-and-sustainability-update.pdf
  122. https://prod1.novartis.com/investors/shareholder-information/general-meetings
  123. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-en.pdf
  124. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-de.pdf
  125. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-media-release-fr.pdf
  126. https://prod1.novartis.com/sites/novartis_com/files/2023-02-interim-financial-report-en.pdf
  127. https://prod1.novartis.com/sites/novartis_com/files/q4-2022-investor-presentation.pdf
  128. https://prod1.novartis.com/sites/novartis_com/files/2023-02/q4-2022-investor-presentation.mp3
  129. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q4-and-full-year-results-transcript
  130. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-february-2023-update.pdf
  131. https://prod1.novartis.com/sites/novartis_com/files/2023-new-novartis-pure-play-innovative-medicines-company.pdf
  132. https://prod1.novartis.com/sites/novartis_com/files/2023-01/2023-new-novartis-pure-play-innovative-medicines-company.mp3
  133. https://prod1.novartis.com/node/546201/printable/print
  134. https://prod1.novartis.com/node/546201/printable/pdf
  135. https://prod1.novartis.com/node/126531
  136. https://prod1.novartis.com/sites/novartis_com/files/2022-12-13-iptacopan-ash-update-presentation.pdf
  137. https://prod1.novartis.com/sites/novartis_com/files/2022-12/2022-12-13-iptacopan-ash-update-presentation.mp3
  138. https://prod1.novartis.com/news/media-releases/novartis-presents-pivotal-phase-iii-apply-pnh-data-ash-demonstrating-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5
  139. https://prod1.novartis.com/sites/novartis_com/files/2022-11-novartis-investor-update-access-sustainability.pdf
  140. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-media-release-en.pdf
  141. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-media-release-de.pdf
  142. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-media-release-fr.pdf
  143. https://prod1.novartis.com/sites/novartis_com/files/2022-10-interim-financial-report-en.pdf
  144. https://prod1.novartis.com/sites/novartis_com/files/q3-2022-investor-presentation.pdf
  145. https://prod1.novartis.com/sites/novartis_com/files/2022-10/q3-2022-investor-presentation.mp3
  146. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q3-transcript
  147. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-october-2022-update.pdf
  148. https://prod1.novartis.com/sites/novartis_com/files/2022-novartis-meet-management-agenda.pdf
  149. https://prod1.novartis.com/sites/novartis_com/files/2022-09-meet-novartis-management-event-presentation.pdf
  150. https://prod1.novartis.com/sites/novartis_com/files/2022-09-meet-novartis-management-event-speakers.pdf
  151. https://prod1.novartis.com/news/media-releases/novartis-unveils-new-focused-strategy-underpinned-eight-potential-multi-billion-dollar-peak-sales-brands-deep-pipeline-meet-management-event
  152. https://prod1.novartis.com/sites/novartis_com/files/2022-08/2022-novartis-sandoz-spinoff-presentation.mp3
  153. https://prod1.novartis.com/sites/novartis_com/files/2022-novartis-sandoz-spinoff-presentation.pdf
  154. https://prod1.novartis.com/news/media-releases/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin
  155. https://prod1.novartis.com/news/media-releases/novartis-will-das-sandoz-geschaft-durch-eine-hundertprozentige-ausgliederung-als-eigenstandiges-unternehmen-abspalten
  156. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-media-release-en.pdf
  157. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-media-release-de.pdf
  158. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-media-release-fr.pdf
  159. https://prod1.novartis.com/sites/novartis_com/files/2022-07-interim-financial-report-en.pdf
  160. https://prod1.novartis.com/sites/novartis_com/files/q2-2022-investor-presentation.pdf
  161. https://prod1.novartis.com/sites/novartis_com/files/2022-07/q2-2022-investor-presentation.mp3
  162. https://prod1.novartis.com/investors/financial-data/quarterly-results/2022-q2-transcript
  163. https://prod1.novartis.com/sites/novartis_com/files/environmental-social-and-governance-july-2022-update.pdf
  164. https://prod1.novartis.com/node/126531/printable/print
  165. https://prod1.novartis.com/node/126531/printable/pdf